News

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in ...
Mira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathy
MIRA Pharmaceuticals (MIRA) announced data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of ...
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, ...
Psychedelic: MindMed announces dosing in Phase 3 Emerge study
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on dosing, data on a ketamine ...
Zacks Small Cap Research on MSN2d
MIRA Continues Positive Testing Run
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Is Microsoft (MSFT) the Best Machine Learning Stock to Buy Now?
We recently published a list of the 10 Best Machine Learning Stocks to Buy Now. In this article, we are going to take a look ...